Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.

Clinically known as benign prostatic hyperplasia (BPH), enlarged prostate is a non‑cancerous condition that affects roughly half of men ages 51 to 60, with incidence increasing ...

The cast of Emmerdale have spoken out following tonight's huge episode in which Cain Dingle revealed the truth to his wife ...

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

This article was reviewed by Knox Beasley. Key Takeaways: 1mg oral finasteride effectively treats hair loss and is the ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic prostate cancer.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with cancer more than a decade ago - but he still lives with the disease.

John Tesh reveals he was given 18 months to live after a rare metastatic prostate cancer diagnosis. Here are the details.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ ...